48 Stocks Moving In Thursday's Mid-Day Session

Gainers

• ASV Holdings, Inc. ASV shares jumped 280.2% to $6.73 after the company reported a merger deal with Yanmar Holdings at $7.05 per share in cash.
• Cemtrex, Inc. CETX shares surged 138.2% to $4.3601 after the company's electronic manufacturing services unit won a $6 million in new orders over the last few months.
• Adaptive Biotechnologies Corporation ADPT shares jumped 90% to $38.00 after pricing 15 million share IPO at $20 per share.
• BridgeBio Pharma, Inc. BBIO shares climbed 58.8% to $26.99 after pricing its IPO at $17 per share.
• The Howard Hughes Corporation HHC rose 37.4% to $127.18 after the company hired Centerview Partners to explore strategic alternatives, including a sale.
• Evoke Pharma, Inc. EVOK climbed 29.2% to $0.69 after the company requested a Type A FDA meeting to plan for the resubmission of Gimoti NDA.
• Atossa Genetics Inc ATOS gained 29.1% to $2.8791 after the company reported that its preliminary Phase 2 Study achieved its primary endpoint for the topical Endoxifen that rapidly reduces breast density.
• Morphic Holding, Inc. MORF rose 22.4% to $18.36 after pricing its IPO at $15 per share.
• Zogenix, Inc. ZGNX gained 19.6% to $47.15 after the company reported an FDA deal to proceed with the resubmission of its FINTEPLA new drug application.
• OFG Bancorp OFG gained 15.9% to $23.90 after the company announced the purchase of Scotiabank operations in Puerto Rico and US Virgin Islands for $550 million in cash.
• Herman Miller, Inc. MLHR rose 15.7% to $43.76 after the company reported stronger-than-expected results for its fourth quarter and raised its quarterly dividend from $0.1975 to $0.21 per share.
• Akerna Corp. KERN shares gained 14.8% to $23.61.
• DelMar Pharmaceuticals, Inc. DMPI surged 14.6% to $1.3637 after the company announced it terminated a rights offering.
• Novavax, Inc. NVAX rose 13.8% to $6.30 after the company entered a strategic partnership with Catalent Biologics. The company also announced it will utilize the accelerated approval pathway for licensure of NanoFlu.
• Dova Pharmaceuticals Inc DOVA shares gained 13.3% to $12.01 after the company reported FDA approval of its supplemental New Drug Application for DOPTELET, expanding the use to include treatment of thrombocytopenia in adults with ITP.
• Peak Resorts, Inc. SKIS climbed 12.7% to $4.45 after the company reported better-than-expected Q4 EPS and sales results.
• Aptinyx Inc. APTX gained 12.4% to $3.54.
• Applied Optoelectronics, Inc. AAOI rose 12.1% to $10.64 after Rosenblatt upgraded the stock from Sell to Neutral, and announced a $10 per share price target.
• Axsome Therapeutics, Inc. AXSM climbed 11.8% to $25.08.
• Tricida, Inc. TCDA rose 11.7% to $39.14.
• Greenlane Holdings, Inc. GNLN gained 10.7% to $10.03.
• AVROBIO, Inc. AVRO surged 10.6% to $15.90.
• Odonate Therapeutics, Inc. ODT shares gained 10.1% to $34.96.
• Puyi Inc. PUYI shares surged 10% to $10.79.
• Apogee Enterprises, Inc. APOG rose 9.3% to $43.05 after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 guidance above analyst estimates.
• Akorn, Inc. AKRX shares climbed 9% to $5.23.
• FuelCell Energy Inc FCEL gained 8.8% to $0.1918 after the company reported a contract with Drax Power Station in the UK for the application of the company's Carbon Capture Solution. No terms are disclosed as of yet.
• The Peck Company, Inc. PECK rose 8.6% to $7.11 after the company announced a $17 million dollar agreement to construct a portfolio of solar arrays generating 7 megawatts.
• 360 Finance, Inc. QFIN gained 8% to $11.94. 360 Finance reported pricing of upsized follow-on offering of 9.609 million ADSs at $10 per ADS.
• Rite Aid Corporation RAD rose 7.8% to $7.67. Rite Aid reported a wider-than-expected loss for its first quarter.
• TripAdvisor, Inc. TRIP gained 6% to $46.70 after DA Davidson upgraded the stock from Neutral to Buy, citing improving fundamentals.
• KB Home KBH rose 5.8% to $24.90 after the company reported better-than-expected Q2 EPS and sales results. KeyBanc upgraded KB Home from Sector Weight to Overweight.
• Seelos Therapeutics, Inc. SEEL rose 5.4% to $2.35 after news emerged the company acquired the license of gene therapy program to address Parkinson's disease from Duke University. The gene therapy program targets the regulation of the SNCA gene. Seelos plans to study this approach, named SLS-004, initially in Parkinson’s disease.
• CenturyLink, Inc. CTL rose 4.6% to $11.42. Wells Fargo upgraded CenturyLink from Market Perform to Outperform.

Check out these big penny stock gainers and losers

Losers

• XpresSpa Group Inc XSPA shares tumbled 57% to $2.02 after a third amendment to outstanding secured convertible notes due November 17, 2019, resulting in added ~941,000 shares to outstanding common stock count.
• Aclaris Therapeutics Inc ACRS shares fell 48.5% to $2.29 after the company reported Phase 2 Trial results for ATI-502 did not meet its primary or secondary endpoints.
• DPW Holdings Inc DPW dropped 34% to $0.2475 after the company stock rose over 100% yesterday in sympathy with Bitcoin.
• Zynex, Inc. ZYXI fell 22.3% to $8.15 after reporting a 16.66 million share common stock offering via selling shareholders.
• Marathon Patent Group, Inc. MARA fell 17% to $2.8649 after rising 29.21% on Wednesday.
• Riot Blockchain, Inc. RIOT fell 15.1% to $3.2164 after rising 14.85% on Wednesday.
• Spero Therapeutics, Inc. SPRO fell 13.1% to $11.14.
• Spherix Incorporated SPEX fell 12.9% to $2.57 after surging 29.96% on Wednesday.
• Conagra Brands Inc CAG fell 12.7% to $25.28 after the company posted downbeat Q4 results and lowered FY20 outlook.
• Motus GI Holdings Inc MOTS fell 11.8% to $3.15 after the company reported the pricing of a common stock offering for 6.66 million shares at $3 per share.
• Net Element, Inc. NETE dropped 7.7% to $4.3558.
• Patterson Companies, Inc. PDCO fell 5.7% to $23.44 after the company posted downbeat Q4 earnings and issued weak FY20 earnings forecast.
• Pier 1 Imports, Inc. PIR fell 4.1% to $8.42 after reporting first-quarter results. Pier 1 reported a greater EBITDA loss than expected and worse-than-expected sales results.
• Advaxis, Inc. ADXS fell 4% to $2.16 after the company announced plans to increase focus on neoantigen-directed immunotherapies. The company also announced it is closing AIM2CERV Phase 3 trial with axalimogene filolisbac.